News & More
Here you will find the most up to date news
and press releases in the bispecific antibody space.
|Oxis Biotech Scientific Advisory Board Member to Address World Summit on Cancer Research|
Amgen reports positive results from phase 2 study of Blincyto in patients with relapsed/refractory PH+ B-cell precursor ALL
Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/ Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia